Latest news with #SchallLawFirm
Business Wire
a day ago
- Business
- Business Wire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against UroGen Pharma Ltd. ('UroGen' or 'the Company') (NASDAQ: URGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2023 and May 15, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before July 28, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. UroGen's ENVISION clinical study for UGN-102 failed to demonstrate evidence of effectiveness due to its design lacking a concurrent control arm. The Company struggled to demonstrate that its duration of response endpoint could be attributed to UGN-102. The Company ignored warnings from the FDA related to its study design. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about UroGen, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
3 days ago
- Business
- Business Wire
META Investors Have Opportunity to Join Meta Platforms, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Meta Platforms, Inc. ('Meta' or 'the Company') (NASDAQ: META) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Meta is the subject of an article published by the Wall Street Journal on May 15, 2025, titled: "Meta Is Delaying the Rollout of Its Flagship AI Model." The article claims that "Company engineers are struggling to significantly improve the capabilities of its "Behemoth" large-language model, leading to staff questions about whether the improvements over prior versions are significant enough to justify public release." The article adds, "Behemoth was internally slated for an April release," but the Company "pushed an internal target for . . . Behemoth's release to June" before delaying it until later in the year. Based on this news, shares of Meta fell by nearly 2.9% in the following two trading sessions. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
3 days ago
- Business
- Business Wire
TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tempus AI, Inc. ('Tempus' or 'the Company') (NASDAQ: TEM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Tempus is the subject of a report published by Spruce Point Capital Management on May 28, 2025. The report describes 'concerns' about the Company such as its alleged use of 'aggressive accounting and financial reporting,' board members and 'other executives have been associated with troubled companies that restated financial results,' and that key partnerships that 'merit scrutiny.' Based on this news, shares of Tempus fell by more than 19.2%. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
4 days ago
- Business
- Business Wire
RCAT Investors Have Opportunity to Lead Red Cat Holdings, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, has filed a class action lawsuit against Red Cat Holdings, Inc. ('Red Cat' or 'the Company') (NASDAQ: RCAT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 18, 2022 and January 15, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before July 22, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Red Cat's overstated the production capacity of its Salt Lake City facility. The Company also overstated the value of its Short Range Reconnaissance Program of Record Tranche 2 contract (the 'SRR Contract'). Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Red Cat, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
5 days ago
- Business
- Business Wire
OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organon & Co. ('Organon' or 'the Company') (NYSE: OGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2024 and April 30, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before July 22, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Organon concealed crucial information about its capital allocation priorities including the future of its quarterly dividend payout. The Company's rosy reports of quarterly dividends as its 'number one priority' were in direct opposition of its debt reduction strategy, which led to a dividend reduction of 70%. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Organon, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
